ARTICLE | Targets & Mechanisms
Blueprint for selectivity
Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP
October 25, 2018 10:55 PM UTC
Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in development.
Blueprint is betting high selectivity and precision targeting will give its IND-ready BLU-782 a better benefit-risk profile than others in the field. It plans to test the compound in healthy volunteers in 1Q19...